GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » Construction In Progress

Immunoclin (Immunoclin) Construction In Progress : $0.00 Mil (As of Oct. 2014)


View and export this data going back to 2012. Start your Free Trial

What is Immunoclin Construction In Progress?


Immunoclin Construction In Progress Historical Data

The historical data trend for Immunoclin's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin Construction In Progress Chart

Immunoclin Annual Data
Trend Feb12 Jan13 Jan14
Construction In Progress
- - -

Immunoclin Quarterly Data
May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Apr14 Jul14 Oct14
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunoclin Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Immunoclin (Immunoclin) Business Description

Traded in Other Exchanges
N/A
Address
9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210
Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines